SyntekaBio

SyntekaBio R&D per Employee

The R&D Spending per Employee of SyntekaBio (226330.KQ) as of Nov 20, 2026 is 47.72 M KRW. In the previous year, R&D Spending per Employee was 61.20 M KRW — a change of -22.03% (lower).

R&D per Employee

47.72 MKRW

YoY

-22.03%

Last updated:

R&D Spending per Employee of SyntekaBio is 2025 47.72 M KRW. R&D Spending per Employee of SyntekaBio was 2024 61.20 M KRW. It decreases by -22.03% lower compared to the previous year.

The SyntekaBio R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2019
34.41 M KRW
Jan 1, 2020
43.91 M KRW
Jan 1, 2021
64.60 M KRW
Jan 1, 2022
66.18 M KRW
Jan 1, 2023
67.18 M KRW
Jan 1, 2024
61.20 M KRW
Jan 1, 2025
47.72 M KRW
The SyntekaBio R&D per Employee history
YEARR&D per EmployeeYoY
47.72 MKRW-22.03%
61.20 MKRW-8.91%
67.18 MKRW+1.52%
66.18 MKRW+2.45%
64.60 MKRW+47.11%
43.91 MKRW+27.60%
34.41 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SyntekaBio Stock analysis

What does SyntekaBio do? SyntekaBio Inc. provides bioinformatics solutions through AI-driven software and services. The company develops and sells PMAP, a personal algorithm dielectric map platform using artificial intelligence, and offers clinical trial modeling and genome analysis services via big data. These services diagnose genetic diseases, select biomarker treatments, and predict disease risk. SyntekaBio also develops AI drug development technology and provides research services for candidate substances of immuno-cancer drugs. The primary customers for SyntekaBio's products include healthcare providers, research institutions, and pharmaceutical companies. Healthcare providers use the diagnostic and predictive services for patient care, while research institutions and pharmaceutical firms utilize the genome analysis and drug development technologies. The company's AI-driven tools are tailored to meet the needs of these segments, focusing on precision medicine and oncology applications. SyntekaBio's revenue streams come from software sales, service contracts for clinical trial modeling and genome analysis, and research services for immuno-cancer drug candidates. The company's AI drug development technology is a key offering, targeting pharmaceutical companies seeking to accelerate drug discovery and development processes. The firm's focus on AI and big data analytics positions it as a provider of specialized solutions in the bioinformatics sector. SyntekaBio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SyntekaBio stock

R&D Spending per Employee of SyntekaBio is 47.72 M KRW in 2025.

R&D Spending per Employee of SyntekaBio changed from 61.20 M KRW to 47.72 M KRW, representing a -22.03% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee SyntekaBio since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's SyntekaBio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — SyntekaBio

All Key Metrics — SyntekaBio